Clinical Trials

624 enrolled 17 charts

Breast Neoplasms

NCT06016738 2026-03-13

OPERA-01

510 enrolled

Breast Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06982521 2026-03-03

ReDiscover-2

540 enrolled

Breast Neoplasms

NCT05038735 2026-02-20

EPIK-B5

212 enrolled

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

210 enrolled

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

420 enrolled

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

Breast Neoplasms

NCT05696626 2026-01-26

ELAINEIII

500 enrolled

Breast Neoplasms

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

1,473 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06635447 2026-01-13

CAPItrue

300 enrolled

Breast Neoplasms, Disease Progression

NCT06764186 2026-01-13

CAPItana

101 enrolled

Breast Neoplasms

NCT05365178 2026-01-07

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

432 enrolled

HR-positive, HER2-negative Breast Neoplasms

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

312 enrolled

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

460 enrolled

Breast Neoplasms

NCT04851613 2025-09-16

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

256 enrolled

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

27 enrolled

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT06998108 2025-05-31

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

330 enrolled

Breast Neoplasms

NCT06954961 2025-05-02

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

640 enrolled

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

312 enrolled

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

275 enrolled

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

287 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

184 enrolled

Advanced Breast Cancer

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT05077449 2024-05-24

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

300 enrolled

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

5 enrolled

Breast Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT05433480 2023-07-27

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Phase 3 Unknown

274 enrolled

Breast Neoplasms

NCT00545077 2023-03-31

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

380 enrolled 21 charts

Breast Neoplasms

NCT03447132 2023-03-10

SAFIA

354 enrolled

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

41 enrolled

Breast Neoplasms

NCT04263298 2022-09-30

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

210 enrolled

Breast Neoplasms

NCT02340221 2022-07-12

SANDPIPER

Phase 3 Terminated

631 enrolled 49 charts

Breast Neoplasms

NCT03927456 2021-06-03

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 3 Unknown

357 enrolled

Advanced Breast Cancer

NCT01610284 2020-08-25

BELLE-2

1,147 enrolled 20 charts

Phase 3 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04337658 2020-04-08

FAVOR

493 enrolled

Breast Neoplasms

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

295 enrolled 18 charts

Breast Neoplasms

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts